Abstract
Most viral gene delivery systems utilized to date have demonstrated significant limitations in practicality and safety due to the level and duration of recombinant transgene expression as well as their induction of host immunogenicity to vector proteins. Recombinant adeno-associated virus (rAAV) vectors appear to offer a vehicle for safe, long-term therapeutic gene transfer; factors afforded through the propensity of rAAV to establish long-term latency without deleterious effects on the host cell and the relative non-immunogenicity of the virus or viral expressed transgenes. The principal historical limitation of this vector system, efficiency of rAAV-mediated transduction, has recently observed a dramatic increase as the titer, purity, and production capacity of rAAV preparations have improved. In terms of systems that could benefit from such improvements, rAAV gene therapy to enhance solid organ transplantation would appear an obvious choice with islet transplantation forming a promising candidate due to the ability to perform viral transductions ex vivo. Currently, islet transplantation can be used to treat type 1 diabetes yet persisting alloimmune and autoimmune responses represent major obstacles to the clinical success for this procedure. The delivery of transgenes capable of interfering with antigenic recognition and/or cell death (e.g., Fas ligand (FasL), Bcl-2, Bcl-X L ) as well as imparting tolerance immunoregulation [e.g., interleukin(IL)-4, IL-10, transforming growth factor (TGF)?b], or cytoprotection [e.g., heme oxygenase-1 (HO-1), catalase, manganese superoxide dismutase (MnSOD)) may prevent recurrent type 1 diabetes in islet transplantation and offer a promising form of immunotherapy. Research investigations utilizing such systems may also provide information vital to understanding the immunoregulatory mechanisms critical to the development of both alloimmune and autoimmune islet cell rejection mechanisms and recurrent type 1 diabetes.
Keywords: Adeno-Associated Virus, Pancreatic Islet, Type 1 Diabetes, Transplantation, rAAV, DIABETES, T cell activation, Immunomodulation, Cell death, apoptosis, oxidative damage
Current Molecular Medicine
Title: Adeno-Associated Virus (AAV) as a Vehicle for Therapeutic Gene Delivery Improvements in Vector Design and Viral Production Enhance Potential to Prolong Graft Survival in Pancreatic Islet Cell Transplantation for the Reversal of Type 1 Diabetes.
Volume: 1 Issue: 2
Author(s): M. H. Kapturczak, T. Flotte and M. A. Atkinson
Affiliation:
Keywords: Adeno-Associated Virus, Pancreatic Islet, Type 1 Diabetes, Transplantation, rAAV, DIABETES, T cell activation, Immunomodulation, Cell death, apoptosis, oxidative damage
Abstract: Most viral gene delivery systems utilized to date have demonstrated significant limitations in practicality and safety due to the level and duration of recombinant transgene expression as well as their induction of host immunogenicity to vector proteins. Recombinant adeno-associated virus (rAAV) vectors appear to offer a vehicle for safe, long-term therapeutic gene transfer; factors afforded through the propensity of rAAV to establish long-term latency without deleterious effects on the host cell and the relative non-immunogenicity of the virus or viral expressed transgenes. The principal historical limitation of this vector system, efficiency of rAAV-mediated transduction, has recently observed a dramatic increase as the titer, purity, and production capacity of rAAV preparations have improved. In terms of systems that could benefit from such improvements, rAAV gene therapy to enhance solid organ transplantation would appear an obvious choice with islet transplantation forming a promising candidate due to the ability to perform viral transductions ex vivo. Currently, islet transplantation can be used to treat type 1 diabetes yet persisting alloimmune and autoimmune responses represent major obstacles to the clinical success for this procedure. The delivery of transgenes capable of interfering with antigenic recognition and/or cell death (e.g., Fas ligand (FasL), Bcl-2, Bcl-X L ) as well as imparting tolerance immunoregulation [e.g., interleukin(IL)-4, IL-10, transforming growth factor (TGF)?b], or cytoprotection [e.g., heme oxygenase-1 (HO-1), catalase, manganese superoxide dismutase (MnSOD)) may prevent recurrent type 1 diabetes in islet transplantation and offer a promising form of immunotherapy. Research investigations utilizing such systems may also provide information vital to understanding the immunoregulatory mechanisms critical to the development of both alloimmune and autoimmune islet cell rejection mechanisms and recurrent type 1 diabetes.
Export Options
About this article
Cite this article as:
Kapturczak H. M., Flotte T. and Atkinson A. M., Adeno-Associated Virus (AAV) as a Vehicle for Therapeutic Gene Delivery Improvements in Vector Design and Viral Production Enhance Potential to Prolong Graft Survival in Pancreatic Islet Cell Transplantation for the Reversal of Type 1 Diabetes., Current Molecular Medicine 2001; 1 (2) . https://dx.doi.org/10.2174/1566524013363979
DOI https://dx.doi.org/10.2174/1566524013363979 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Oxazolidines Inhibit the Secretion of IFN-γ and IL-17 by PBMCS from Moderate to Severe Asthmatic Patients
Medicinal Chemistry The Alzheimer Pandemic: Is Paracetamol to Blame?
Inflammation & Allergy - Drug Targets (Discontinued) Good, Bad, Mobile Elements: Genome’s Most Successful “Parasites” as Emerging Players in Cell and Organismal Aging
Current Pharmaceutical Design Prophylactic Effect of Monosodium Glutamate on NSAID-Induced Enteropathy in Rats
Current Pharmaceutical Design Modulation of MMP-9 Pathway by Lycopene in Macrophages and Fibroblasts Exposed to Cigarette Smoke
Inflammation & Allergy - Drug Targets (Discontinued) Endocrinology and Immunology of Obesity, Obesity Vaccines
Current Clinical Pharmacology Delayed Developmental Effects Following Prenatal Exposure to Drugs
Current Pharmaceutical Design Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry Microdose Lithium NP03 Diminishes Pre-Plaque Oxidative Damage and Neuroinflammation in a Rat Model of Alzheimer’s-like Amyloidosis
Current Alzheimer Research Cerebrovascular Damage as a Cause for Alzheimers Disease
Current Neurovascular Research The Role of Zinc in the Treatment of Taste Disorders
Recent Patents on Food, Nutrition & Agriculture Mechanism of Idiosyncratic Drug Reactions: Reactive Metabolites Formation, Protein Binding and the Regulation of the Immune System
Current Drug Metabolism Does Inhaled Corticosteroid Treatment Result in a Secondary Immune Deficiency Predisposing To Recurrent Infections?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nanowired Drug Delivery to Enhance Neuroprotection in Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets The Role of Microglial Cell Subsets in Alzheimers Disease
Current Alzheimer Research Phytosterols and Inflammation
Current Medicinal Chemistry Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Editorial (Thematic Issue: New Therapeutic Options for Anxiety and Mood Disorders)
CNS & Neurological Disorders - Drug Targets The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential.
Current Medicinal Chemistry